Sigma Planning Corp Reduces Holdings in Cue Biopharma, Inc. (NASDAQ:CUE)

Sigma Planning Corp decreased its position in shares of Cue Biopharma, Inc. (NASDAQ:CUE) by 55.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 108,875 shares of the company’s stock after selling 135,830 shares during the quarter. Sigma Planning Corp’s holdings in Cue Biopharma were worth $287,000 as of its most recent SEC filing.

Separately, Navalign LLC acquired a new stake in shares of Cue Biopharma during the fourth quarter worth about $66,000. 35.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Stifel Nicolaus reaffirmed a “buy” rating and set a $8.00 target price on shares of Cue Biopharma in a report on Tuesday, April 9th. Jefferies Financial Group assumed coverage on Cue Biopharma in a report on Wednesday, March 13th. They set a “buy” rating and a $6.00 target price for the company. Oppenheimer reaffirmed an “outperform” rating and set a $10.00 target price on shares of Cue Biopharma in a report on Tuesday, April 9th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $8.00 target price on shares of Cue Biopharma in a report on Wednesday, April 3rd.

Cue Biopharma Trading Down 3.2 %

Shares of NASDAQ:CUE opened at $1.37 on Friday. Cue Biopharma, Inc. has a 12-month low of $1.30 and a 12-month high of $5.12. The company has a market capitalization of $66.39 million, a PE ratio of -1.24 and a beta of 2.02. The business has a 50 day moving average of $1.87 and a two-hundred day moving average of $2.29. The company has a current ratio of 3.01, a quick ratio of 3.01 and a debt-to-equity ratio of 0.11.

Cue Biopharma (NASDAQ:CUE) last announced its quarterly earnings results on Monday, April 8th. The company reported ($0.28) earnings per share (EPS) for the quarter. Cue Biopharma had a negative net margin of 924.10% and a negative return on equity of 112.26%. The company had revenue of $1.82 million during the quarter. As a group, analysts forecast that Cue Biopharma, Inc. will post -1 EPS for the current year.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.